Gastrointestinal Tumors: Prevention, Screening and Predictive Analytics

Dear Colleagues,

Gastrointestinal (GI) tumors remain one of the leading causes of cancer morbidity and mortality worldwide. Progress in prevention, screening, and predictive analytics is crucial for shifting diagnosis to an earlier stage, tailoring risk, and reducing disparities.

This Special Issue invites original research articles and reviews that advance the prevention, risk assessment, or early detection of GI and hepatobiliary malignancies. We welcome studies on population and genetic risk models, biomarkers (including blood- and stool-based assays, ctDNA/methylation signatures, proteomics, and the microbiome), imaging and radiomics approaches for early detection, comparative effectiveness of screening strategies and pathways, chemoprevention strategies, agents, and trials, and AI/ML models integrating clinical, laboratory, endoscopic, and imaging data. Submissions emphasizing methodological rigor, transparent reporting, calibration, external validation/transportability, decision-analytic evaluation, and implementation science (including uptake, adherence, and equity) are particularly encouraged. Additionally, analyses of feasibility and cost-effectiveness in diverse health systems are also encouraged. To maintain a focus on early detection and risk, submissions centered primarily on therapeutic interventions or survivorship without a clear prevention, screening, or prediction component are outside the scope of this Special Issue.

We look forward to contributions that can be translated into practical applications and policies to meaningfully improve outcomes across the GI cancer control continuum.

You may choose our Joint Special Issue in Current Oncology.

Dr. Mohamed I. Elsaid
Prof. Dr. Electra D. Paskett
Prof. Dr. Vinod Rustgi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.